Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Achieving improvements in survival and reducing relapse remains a challenge in acute myelogenous leukemia (AML) patients. This study evaluated the in vitro efficacy of the active form of novel agent sapacitabine, CNDAC, compared to current chemotherapeutic drugs Ara-C and mitoxantrone using two AML...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jagan, Sucheta, Paganessi, Laura A., Frank, Robin R., Venugopal, Parameswaran, Larson, Melissa, Christopherson, Kent W.
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2012
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461608/
https://ncbi.nlm.nih.gov/pubmed/23049558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/727683
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky